A Review on Antimalarial 1,2,4-Trioxane Derivatives

Choudhary Amit1, Sinha Manish1, Devi Arti1, Jindal Shammy2, Goyal Kamya1*

1Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog, Distt-Kangra, H.P., India
2Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Distt-Kangra, H.P., India

ABSTRACT

Malaria in recent years becomes a major health hitch globally due to the surfacing of multidrug-resistant strains of Plasmodium falciparum parasite. In recent times, artemisinin (ART)-based drugs and combination therapies become the drugs of preference for the treatment and prophylaxis of resistant P. falciparum malaria. Endoperoxide compounds natural, semi-synthetic or synthetic signifying a massive number of antimalarial agents which possess a wide structural miscellany with needed antimalarial effectiveness against resistant P. falciparum malaria. The 1,2,4-trioxane ring system deficient the lactone ring which constitutes the most significant endoperoxide structural scaffold which is believed to be the key pharmacophoric moiety and is principally responsible for the pharmacodynamic potential of endoperoxide-based antimalarials. This becomes the main reason for the research related to endoperoxide particularly 1,2,4-trioxane-, 1,2,4-trioxane- and 1,2,4,5-tetraoxane-based scaffolds gaining the noteworthy interest in recent years for developing antimalarial drugs against resistant malaria. In this paper, a comprehensive endeavour has been made to review the development of different endoperoxide antimalarial agents and structural diversity of endoperoxide molecules derived from 1,2,4-trioxane-based structural scaffolds.

Keywords: Endoperoxide, 1,2,4-trioxane; pharmacophores; artemisinin; antimalarial.

1. INTRODUCTION

Malaria is the broadest tropical parasitic disease and is brought about by contaminations of protozoan parasites of the variety Plasmodium and transmitted to man by specific types of tainted female Anopheles mosquito. It is one of humankind’s oldest and the broadest irresistible diseases on the planet today, exists in more than 100 nations including the United States. Around 40% of the entire population is in danger of malaria contamination, and every year, in excess of 250 million individuals experience malarial ailment and over 1.5 million person’s die.

1.1. Causative agents

Malaria is brought about by five types of the parasite Plasmodium, to be specific P. falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi and these, P. falciparum is mainly perilous and destructive species that cause serious malaria, for example, cerebral malaria and is conscious for the majority of deaths from malaria in humans.

1.2. Signs and symptoms

Malaria infection is usually characterized by the following signs and symptoms such as high fever, diarrhoea, anemia, muscle pain, abdominal pain, convulsions, coma, chill, sweating, bloody stools, headache, vomiting, nausea.

1.3. Life cycle of malaria parasite

The life cycle of malaria parasites includes two hosts, humans and Anopheles mosquitoes. The disease is conveyed to human by a bite of an infected Anopheles mosquito that introduces the sporozoites of plasmodia into the human's blood. The sporozoites pass through the blood to the liver, where they grow-up, and finally infect the human red blood cells. Intraerythrocytic parasites either continue asexual reproduction to produce more Merozoites, which can attack other erythrocytes or can develop into gametocytes that are capable of infecting the next hungry mosquito. At that point, the parasites enter the stomach of Anopheles mosquito and eventually attack the mosquito salivary organs. When an Anopheles mosquito bites a human, these sporozoites complete and repeat the complicated Plasmodium life cycle.
1.4. Global disease burden

As per the report of WHO (2018) 219 million instances of malaria were anticipated to occur globally in 2017 compared to 239, 214 and 217 million instances, respectively in 2010, 2015 and 2016. Approximately 20 million fewer instances of malaria were recorded in 2017 than in 2010 and no important improvement was shown in this timeframe in decreasing worldwide instances of malaria. Most cases of malaria were in the African region in 2017 (200 million or 92%), followed by the South-East Asian region (5%), the East Mediterranean region (2%). Including India and 15 countries in sub-Saharan Africa accounted for nearly 80% of the global malaria burden and 274,000 deaths worldwide in 2017. However; India reported 3 million cases during the period of 2016-2017. *P. falciparum* is the predominant malaria species in the african area, accounting for 99.7% of expected disease case in 2017, as well as in South-East Asia (62.8%), the Eastern Mediterranean (69%) and the Western Pacific (71.9%) and also *P. vivax* is America’s predominant malaria parasite (74.1 per cent).

1.5. Classification

The antimalarial drugs are classified according to chemical structure.

| Class | Drug |
|-------|------|
| 4-aminoquinolines | Chloroquine, Amodiaquine, Piperaquine |
| Quinolone-methanol | Mefloquine |
| Cinchona alkaloid | Quinine, Quinidine |
| Biguanides | Proguanil (chloroguanide), Chloroguanil |
| Diaminopyrimidines | Pyrimethamine |
| 8-aminoquinoline | Primaquine, Bulaquine, Pamaquine, Tafenoquine |
| Sulfonamides and sulfone | Sulfadoxine, Sulfamethopyrazine, Dapsone |
| Antibiotics | Tetracycline, Doxycycline, Fluoroquinolones, Azithromycin, Clindamycin |
| Sesquiterpene lactone | Artesunate, Artemether, Arteether, Artelinic acid |
| Amino alcohols | Halofantrine, Lumezantrine |
| Naphthaquinones | Atovaquone |
| Mannish base | Pyronaridine |
1.6. 1,2,4-trioxane as a potent antimalarial agent

1,2,4-Trioxane (Fig. 2) is one of the isomers of trioxane. It has a ring-like structure of six members of three carbon and three oxygen atoms with a molecular formula of C₆H₆O₃. A peroxide functional group formed by two adjacent oxygen atoms and the other formed an ether functional group. The peroxide bridge is considered as the most chemically reactive moiety of 1,2,4 trioxanes 21, 22.

Figure 2: 1,2,4-trioxane

1.7. Artemisinin

Artemisinin is a natural 1,2,4-trioxane sesquiterpene isolated from Artemisia annua 23-26 and its byproducts are a powerful class of antimalarial drugs 27. Chemically, artemisinin is a Sesquiterpene-lactone with an unusual peroxide bridge. The peroxide bridge is considered to be the most chemically reactive moiety responsible for antimalarial activity in artemisinin 28.

Artemisinin and its byproducts share a common structural characteristic called endoperoxide linkage 29. Artemisinin usually have bad water or oil solubility. However, a more water-soluble derivative of dihydroartemisinin (DHA) can be achieved, which is more active than artemisinin, by decreasing Artemisinin’s C-10 carbonyl group. By including methyl or ethyl ether at the same carbonyl group, oil-soluble Artether and water-soluble sodium artesunate compounds were obtained. These three Artemisin derivatives become very powerful anti-malarial drugs that are efficient against P. falciparum chloroquine-resistant strains 30-33.

1.7.1. Mechanism of action of Artemisinin

Artemisinin mechanism of action is based on haemoglobin digestion leading to iron-containing heme release. In its molecule, the Endoperoxide Bridge appears to interact with the parasite’s heme. Iron-mediated bridge cleavage to release an extremely reactive free species of radicals selectively targets P. falciparum’s sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase, changing calcium stores. The artemisinin actually may form covalent adduct to particular membrane proteins that cause lipid peroxidation, damage endoplasmic reticulum, inhibit protein synthesis and eventually cause malaria parasite death 34,35.

1.7.2. Artemisinin-based combination therapy

Plasmodium falciparum is a most dangerous species of Plasmodium responsible for severe malaria, such as cerebral malaria. ACTs are currently considered the most beneficial treatment for multidrug-resistant P. falciparum malaria, according to the World Health Organization. As the Plasmodium strains are more resistant to commonly used antimalarial drugs such as chloroquine and sulfadoxine/pyrimethamine. Artemisinin-based combinations therapy include: 35-38

1. Artesunate + Amodiaquine
2. Artemether + Lumefantrine
3. Dihydroartemisinin + Piperaquine
4. Artesunate + Pyronaridine
5. Artesunate + Sulfadoxine + Pyrimethamine
6. Artesunate +Mefloquine

1.7.3. Artemisinin derivatives

Artemisinin and its derivatives such as artether, arteether and artesunic acid are well suited for the treatment of cerebral malaria caused by multidrug-resistant Plasmodium falciparum. These drugs are highly active against both chloroquine-sensitive and resistant malaria 39-47.
Novel series of hydroxy-functionalized 1,2,4-trioxanes

A novel series of hydroxyl-functionalized antimalarial 1,2,4-trioxanes were synthesized for in-vitro Plasmodium falciparum (NF-54 strain). The most active are trioxanes with the adamantane moiety (7d and 8d), while those with 3,3-dimethyl substituent (7a and 8a) are the least active. Trioxane (7d) has also been assessed in Swiss mice for its in-vivo antimalarial efficacy against multi-drug-resistant P. yoelii and demonstrates promising activity. A sequence of novel 1,2,4 trioxanes using an abundant natural product that demonstrates promising antimalarial activity. The novel feature of these trioxanes is the side chain with a hydroxyl bond. This hydroxyl group offers some additional options to make new derivatives of these trioxanes.

Amino functionalised synthetic 1,2,4-trioxanes

A new series of amino functionalised 1,2,4-trioxanes were synthesised (shown in table 2), among these the 9'd compound has very potent action against multi-drug resistance P. yoelii. The compound was further taken for the in vivo profiling against P. yoelii as antimalarial agents, where 9'd compound had shown 100% suppression in Swiss mice on the 4th day and all the mice were alive at the end of the testing period. The most potent compound 9d in the series is very close to that of β-artether.

| Compound no. | Ar            | R               |
|-------------|---------------|-----------------|
| 9a          | Phenyl        | Phenyl          |
| 9b          | Phenyl        | 4- Methoxyphenyl|
| 9c          | Phenyl        | 3,5 dichlorophenyl|
| 9d          | Phenyl        | 4-Acetylamino phenyl|
| 9e          | Phenyl        | 1-Naphthyl      |
| 9'  a       | 4-Biphenyl    | 4-Methoxyphenyl |
| 9'  b       | 4-Biphenyl    | 4-Acetylamino phenyl|
| 9'  c       | 4-Biphenyl    | 1-Naphthyl      |
| 9'  d       | 4-Biphenyl    | Phenyl          |
| 9'  e       | 4-Biphenyl    | 3,5 dichlorophenyl|

Table 2: Amino functionalised 1,2,4 trioxanes
6-cycloalkylvinyl substituted 1, 2, 4-trioxanes

A new series of 6-cycloalkylvinyl substituted 1,2,4-trioxanes were prepared (shown in table 3) by using a photo-oxygenation route and tested in mice against MDR Pyolei by intra-muscular. Trioxane 10a was found the most active compound of the series 50.

Table 3: 6-cycloalkylvinyl substituted

| Compound no. | R       |
|--------------|---------|
| 10a          | Cyclopropyl |
| 10b          | Cyclohexyl |
| 10c          | Phenyl    |

| Compound no. | R        | R₁          | R₂          |
|--------------|----------|-------------|-------------|
| 11a          | Cyclopropyl | H           | Phenyl      |
| 11b          | Cyclopropyl | CH₃         | CH₃         |
| 11c          | Cyclohexyl | CH₃         | CH₃         |

Trans-fused bicyclic 1, 2, 4-trioxanes

Trans-fused bicyclic 1,2,4-trioxanes (shown in table 4) have been prepared by Photo-oxygenation route. Stereoselective photo-oxygenation of 3-aryl-2-cyclohexenols and acid catalyzed condensation of trans-2-hydroperoxy-3-aryl-3-cyclohexenols with aldehydes and ketones are the key steps of this method. Trioxanes 13c, 13′c, 13″c & 14b showed more than 95% suppression of parasitaemia at 96 mg/kg/day by oral route. The most energetic compound of the series is trioxane 14c. It shows a complete suppression of parasitaemia on day 4 51.

Table 4: Trans-fused bicyclic 1, 2, 4-trioxanes

| Compound no. | Ar                  | n     |
|--------------|---------------------|-------|
| 13a-c        | Phenyl, 4- ClC₆H₄, 4- PhC₆H₄ | 1     |
| 13′a-c       | Phenyl, 4- ClC₆H₄, 4- PhC₆H₄ | 2     |
| 13″a-c       | Phenyl, 4- ClC₆H₄, 4- PhC₆H₄ | 3     |
| 14a-c        | Phenyl, 4- ClC₆H₄, 4- PhC₆H₄ |       |
Spiro 1, 2, 4-trioxanes

The next generation of orally effective spiro 1,2,4-trioxanes was prepared (as shown in table 5) and evaluated for their in-vivo antimalarial action against *p. yoelii* in Swiss mice by the oral and i.m. route. All the synthesised compounds showed potential against *p. yoelii* and Trioxane 16a was the series’ most effective compound among them.

Table 5: Spiro 1, 2, 4-trioxanes

| Compound no. | Ar            | R            |
|--------------|---------------|--------------|
| 15a          | 4-biphenyl    |              |
| 15b          | Phenyl        |              |
| 16a          | Phenyl        | H            |
| 16b          | 4-biphenyl    | H            |
| 16c          | 4-biphenyl    | CH₃          |
| 16d          | Phenyl        | CH₃          |
| 17a          | Methyl (higher Rf) |              |
| 17b          | Methyl (lower Rf) |              |
| 17c          | Phenyl (higher Rf) |              |
| 17d          | Phenyl (lower Rf) |              |
| 18a          | Phenyl        |              |
| 18b          | 4-biphenyl    |              |
| 19a          | Phenyl (higher Rf) |              |
| 19b          | Phenyl (lower Rf) |              |
| 19c          | 4-biphenyl (higher Rf) |              |
| 19d          | 4-biphenyl (lower Rf) |              |

Cis-fused cyclopentene-1, 2, 4-trioxanes

A new series of compounds were synthesised having a blood schizontocidal activity 1,2,4-trioxanes against the MDR of *P. yoelii nigeriensis* strain deadly in Swiss mice. The formulations of these compounds were freshly prepared either in neutral groundnut oil or in Tween-DMSO-water and were evaluated for their antimalarial activity. Only two fenozan derivatives 20 and 21 which were formulated in neutral groundnut oil for oral administration, showed maximum activity with 100% treat rate in MDR *P. yoelii nigeriensis* infected mice while the formulations in Tween-DMSO-water were found inactive.

Spiro 1,2,4-trioxanes based on adamantane

A new series of 6-arylvinyl and 6-adamantylvinyl-substituted 1,2,4-trioxanes were synthesised (shown in table 6 and 7) and assessed against multi-drug resistance *P. yoelii nigeriensis* in mice through oral and i.m. route for their antimalarial action. The 6-arylvinyl substituted 1,2,4-trioxanes showed promising activity, whereas all 6-adamantyl substituted 1,2,4-trioxanes were found inactive. Trioxane 22f, the most effective compound of the 6-arylvinyl substituted 1,2,4-trioxanes. The most active compound of the series showed antimalarial activity better than that of arteether and artesunic acid by the oral route.
A new series of orally active steroids based 1,2,4-trioxanes were synthesised (shown in table 8, 9 and 10) and evaluated by oral route for antimalarial activity against MDR Plasmodium yoelii in Swiss mice. The in-vivo antimalarial activity demonstrated that all 1,2,4-trioxanes dependent on pregnane had a substantial effect compared to 1,2,4-trioxanes depending on cholestane and tigogenine. Among the series most active compounds, 1,2,4-trioxanes 24b and 24f are pregnane based. Both trioxanes showed 100 per cent clearance of parasitaemia on day 4 at 96mg / kg/4×day and all treated mice lived after day 28.

**Pregnane-based trioxanes**

| Compound no. | X     |
|--------------|-------|
| 24a          | H     |
| 24b          | CH₃OH |
| 24c          | CH₃   |
| 24d          | F     |
| 24e          | Cl    |
| 24f          | Br    |

**Cholestane based 1,2,4, trioxanes**

| Compound no. | X     |
|--------------|-------|
| 25a          | H     |
| 25b          | CH₃OH |
| 25c          | CH₃   |
| 25d          | F     |
| 25e          | Cl    |
| 25f          | Br    |

**Tigogenine-based trioxanes:**

| Compound no. | X     |
|--------------|-------|
| 26a          | CH₃OH |
| 26b          | CH₃   |
| 26c          | F     |
| 26d          | Cl    |

1,2,4-trioxane based on steroids

![Image](22.png)

![Image](24.png)

![Image](23.png)

![Image](25.png)

![Image](26.png)
Novel bis- and tris-1,2,4-trioxanes

A series of bis-1,2,4-trioxanes have been prepared and evaluated against multidrug-resistant *P. yoelii* in mice by the oral route. These bis-trioxanes have been set up by a minor alteration of photo-oxygenation technique. Basically, these bis-trioxanes are two 6-arylvinyl-1,2,4-trioxane moieties joined by a variety of linkers and their antimalarial activity shows a strong dependence on the nature of the linker. A novel sequence of bis and tri-1,2,4 trioxanes were synthesised (shown in Table 11) and assessed by oral route against *P. yoelii* MDR in Swiss mice. Trioxanes based on cyclopentane 27a, 27b, 27f-h and cyclohexane 28a, 28f and 28g showed promising activity. Trioxane (compound 28a) was the most effective compound in the series, offers 100% and 80% safety at 48 and 24 mg/kg within 4 days. The clinically used arteether showed only 20 % at 24 mg/kg 4 days.

Table 11: Bis- and Tris-1,2,4-trioxanes

| Compound no. | Structure | Compound no. | Structure |
|--------------|-----------|--------------|-----------|
| 27a          | ![Structure](image1) | 28a          | ![Structure](image2) |
| 27b          | ![Structure](image3) | 28b          | ![Structure](image4) |
| 27c          | ![Structure](image5) | 28c          | ![Structure](image6) |
| 27d          | ![Structure](image7) | 28d          | ![Structure](image8) |
| 27e          | ![Structure](image9) | 28e          | ![Structure](image10) |
| 27f          | ![Structure](image11) | 28f          | ![Structure](image12) |
| 27g          | ![Structure](image13) | 28g          | ![Structure](image14) |
| 27h          | ![Structure](image15) | 28h          | ![Structure](image16) |
6-(4-aryloxy-phenyl)vinyl-1, 2, 4-trioxanes

A new 6-(4-aryloxy-phenyl)vinyl-1,2,4-trioxanes sequence have been synthesized (shown in table 12) and evaluated for their antimalarial activity against MDR of *P. yoelii* in Swiss mice after oral administration. The most effective compounds of the sequence are Trioxanes 30b and 30c, Protected the mice 100% at 48 mg/kg × 4 days. These two compounds displayed a similar activity as that of β-arteether.

Table 12: 6-(4-Aryloxy-phenyl)vinyl-1, 2, 4-trioxanes

| Compound no. | Structure | Compound no. | Structure |
|--------------|-----------|--------------|-----------|
| 30a          | ![Structure 30a](image) | 31c          | ![Structure 31c](image) |
| 30b          | ![Structure 30b](image) | 31d          | ![Structure 31d](image) |
| 30c          | ![Structure 30c](image) | 32a          | ![Structure 32a](image) |
| 30d          | ![Structure 30d](image) | 32b          | ![Structure 32b](image) |
| 31a          | ![Structure 31a](image) | 32c          | ![Structure 32c](image) |
| 31b          | ![Structure 31b](image) | 32d          | ![Structure 32d](image) |
1,2,4-trioxane derivatives based on bile acid

A new sequence of bile acid-based 1,2,4-trioxanes have been synthesised (shown in table 13), the antimalarial activity of these trioxanes showed strong dependence both the stereochemistry around trioxanes ring and length of the side chain. Trioxanes is more polar than the less polar one was considerably more active. The more polar trioxane diastereomer 33a, 33b, 33c were the series most effective compounds. All three trioxanes were 100% protected at 24 mg/kg for 4 days and twice active as β-arteether 58.

Table 13: Bile acid-based 1,2,4, trioxanes

| Compound no. | Ar                | Ar                | Ar                | Ar                |
|--------------|-------------------|-------------------|-------------------|-------------------|
| 33a          | Phenyl (less polar isomer) | Phenyl (more polar isomer) | 4-fluorophenyl (less polar isomer) | 4-fluorophenyl (more polar isomer) |
| 33b          | 4-fluorophenyl (less polar isomer) | 4-fluorophenyl (more polar isomer) | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) |
| 33c          | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) |
| 33d          | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) |
| 34a          | Phenyl (less polar isomer) | Phenyl (more polar isomer) | 4-fluorophenyl (less polar isomer) | 4-fluorophenyl (more polar isomer) |
| 34b          | 4-fluorophenyl (less polar isomer) | 4-fluorophenyl (more polar isomer) | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) |
| 34c          | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) |
| 34d          | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) |
| 35a          | Phenyl (less polar isomer) | Phenyl (more polar isomer) | 4-fluorophenyl (less polar isomer) | 4-fluorophenyl (more polar isomer) |
| 35b          | 4-fluorophenyl (less polar isomer) | 4-fluorophenyl (more polar isomer) | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) |
| 35c          | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) |
| 35d          | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) |
| 36a          | Phenyl (less polar isomer) | Phenyl (more polar isomer) | 4-fluorophenyl (less polar isomer) | 4-fluorophenyl (more polar isomer) |
| 36b          | 4-fluorophenyl (less polar isomer) | 4-fluorophenyl (more polar isomer) | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) |
| 36c          | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) |
| 36d          | 4-bromophenyl (less polar isomer) | 4-bromophenyl (more polar isomer) | 4-chlorophenyl (less polar isomer) | 4-chlorophenyl (more polar isomer) |
3, 3-spiro anellated 5, 6-disubstituted 1, 2, 4-trioxanes

Novel 3,3-Spiro anellated 5,6-Disubstituted 1, 2, 4-Trioxanes (shown in table 14) have been synthesized and evaluated for their in-vivo antimalarial activity against multi drugs resistance of *P. yoelii nigeriensis* in Swiss mice by the oral route. The 38b compound of the sequence was most active, protected the mice 100% at 24 mg/kg × 4 days. The other trioxanes 37d, 38c, 38d, 39b also displayed promising activity. The compound 39b showed a similar in-vitro pharmacokinetic profile to β-arteeether.

### Table 14: 3, 3-Spiroanellated 5, 6-Disubstituted 1, 2, 4-Trioxane

| Compound no. | R     |
|--------------|-------|
| 37a          | H     |
| 37b          | Cl    |
| 37c          | CH₃   |
| 37d          | Br    |
| 37e          | F     |
| 38a          | H     |
| 38b          | Cl    |
| 38c          | CH₃   |
| 38d          | Br    |
| 38e          | F     |
| 39a          | H     |
| 39b          | Cl    |
| 39c          | CH₃   |
| 39d          | CH₃OH |
| 39e          | Br    |
| 39f          | F     |

**CDRI compound no. 99/411 is a potent 1,2,4-trioxane antimalarial candidate drug**

The Central Drug Research Institute, Lucknow, India developed 99/411, a novel antimalarial agent that is a semisynthetic derivative of artemisinin. It is a potent 1,2,4-trioxane antimalarial candidate.

**New series of derivatives of 1,2,4-trioxane**

Three new series of 1,2,4-trioxane derivatives were synthesised and appraised in vitro for their antimalarial activity. Substitutions at the C-3 position of 1,2,4-trioxane ring system with different aliphatic, aromatic and heteroaromatic groups afforded target trioxane derivatives (shown in table 15, 16&17) as antimalarial agents, of which three series of 1,2,4 trioxane derivatives, five compounds (41’d, 41’e, 41’b, 41’c, 41’l) exhibited antimalarial activity well in vitro, with three compounds (41’b, 41’l, 41’d) showing greater activity against *Plasmodium falciparum* (RKL9) than sensitive (3D7) one. 41’l and 41’d were the best compounds from the aryl sequence and the other from the heteroaryl sequence.

![Diagram](image-url)
CONCLUSION

The present paper concludes that there are different types of 1,2,4-trioxane derivatives that are synthesised by the different methods for the treatment of malaria. Artemisinin derivatives contain a 1,2,4-trioxane ring which is responsible for the antimalarial activity. Many of the different drugs are used to treat malaria but due to MDR against malaria strains, synthesis of the new artemisinin derivatives is a good approach to treat malaria caused by the different Plasmodium spedes.

REFERENCES

[1] Tang Y, Dong Y, Vennerstrom JL. Synthetic peroxides as antimalarials. Medicinal Research Reviews. 2004; 24(4):425-48.
[2] Transmission of malaria. https://www.malariasite.com/transmission/
[3] Jung M, Lee K, Kim H, Park M. Recent advances in artemisinin and its derivatives as antimalarial and antitumor agents. Current medicinal chemistry. 2004;11(10):1265-84.
[4] Jinky G, Dipak C, Mukesh KK, Mithun R. Synthesis and antimalarial activity evaluation of some mannich bases of tetraoxane antimalarials. Medicinal Research Reviews. 2004; 24(4):425-48.
[5] Garner P, Graves PM. The benefits of artemisinin combination therapy for malaria extend beyond the individual patient. PLoS medicine. 2005;2(4):e105.
[6] Rudrapal M, Chetia D, Singh V. Novel series of 1, 2, 4-trioxane derivatives as antimalarial agents. Journal of enzyme inhibition and medicinal chemistry. 2017;32(1):1159-73.
[7] Singh C, Chaudhary S, Kanchan R, Puri SK. Conversion of antimalarial drug artemisinin to a new series of tricyclic 1, 2, 4-trioxanes. Organic Letters. 2007;9(21):4327-9.
[8] Rudrapal M, Chetia D. Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold. Drug Des Dev Ther 2016; 10:3575–90.
[9] Pandey S, Agarwal P, Srivastava K, Synthesis and bioevaluation of novel 4-aminquinoline-tetraoxole derivatives as potent antimalarial agents. Eur J Med Chem 2013;66:69–81.
[10] Gogoi J, Chetia D, Kumawat MK, Synthesis and antimalarial activity evaluation of some mannich bases of tetraoxane-phenol conjugate. Indian J Pharm Educ Res 2016; 50:591–7.
[11] Kumar V, Abas AK, Fausto N, Oster JC, Robbins and Cotran pathologic basis of disease, professional edition e-book. Elsevier health sciences; 2014.
[12] Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Pharmacotherapy 3rd A. K: A Pathphysiologic Approach. DiPiro JT, editor. Appleton & Lange; 1997.
[13] Sharma GK, Yogi A, Gaur K, Dashora A. A Review On Anti Malarial Drug.
[14] World malaria report 2018. https://www.business-standard.com/article/current-affairs/world-malaria-report-2018-led-by-odisha-india-reduces-cases-by-3-million-n11811230064_1.html
[15] WHO Global malaria report 2018. https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/
[16] Tripathi KD. Essentials of medical pharmacology. JP Medical Ltd; 2013
[17] Dutta GP. New Antimalarial Drug Discovery in India and Future Strategy for Malaria Control. Proceedings of the Indian National Science Academy. 2016;82(1).
[18] Leib B, Kremsner PG. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob agents and chemotherapy. 2002;46(8):2315–20.
[19] Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrobial agents and chemotherapy. 2002;46(8):2518-24.
[20] Mahmoudi N, Cekerov L, Franetić JF, Farhati K, Silve G, Eling W, Sauerwein R, Danis M, Mazier D, Derouin F. In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp. Antimicrobial agents and chemotherapy. 2003;47(8):2636-9.
[21] Posner GH, Parker MH, Northrop J, Elias JS, Ployphadth P, Xie S, Shapiro TA. Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family. Journal of medicinal chemistry. 1999;42(2):300-4.
[22] Cumming IN, Ployphadth P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism (s) of

Table 15: Alkyl series

| Compound no. | R     |
|--------------|-------|
| 41a          | Ethyl |
| 41b          | Propyl|
| 41c          | Butyl |
| 41d          | Pentyl|
| 41e          | 1-formyl-but-4-yl|

Table 16: Heteroaryl series

| Compound no. | R            |
|--------------|--------------|
| 41'a         | Furan-2-yl   |
| 41'b         | Thiophen-2-yl|
| 41'c         | Pyrrole-2-yl |
| 41'd         | Indole-3-yl  |
| 41'e         | Pyridine-4-yl|

Table 17: Aryl series

| Compound | R       | Compound | R     |
|----------|---------|----------|-------|
| 41'a     | Phenyl  | 41'h     | 4-Fluorophenyl |
| 41'b     | 2-Hydroxyphenyl | 41'i     | 1-Naphthyl |
| 41'c     | 3-Methoxyphenyl | 41'j     | 4-Dimethylaminophenyl |
| 41'd     | 4-Chlorophenyl | 41'k     | 4-Cinnamyl |
| 41'e     | 4-Nitrophenyl | 41'l     | 4-Hydroxy-3-methoxyphenyl |
| 41'f     | 4-Tolyl   | 41'm     | 4-Dimethoxyphenyl |
| 41'g     | 4-Bromophenyl | 41'n     | Isophthalyl |
action. In:Advances in pharmacology 1996 (Vol. 37, pp. 253-297). Academic Press.

[23] Reiter C, Fritzsche T, Zeino M, Marschall M, Bahhi J, Leidenberger M, Friedrich O, Kappe B, Hampel F, Effert H, Tsogeeva SB. New efficient artemisinin derived agents against human leukemia cells, human cytomegalovirus and Plasmodium falciparum: 2nd generation 1, 2, 4-trioxane-frozen hybrids. European journal of medicinal chemistry. 2015; 97:64-72.

[24] Li Y, Wu Y. An over four millennium story behind qinghaosu (artemisinin)-a fantastic antimalarial drug from a traditional Chinese herb. Current medicinal chemistry. 2003; 10(21):2197-230.

[25] Laurent SA, Loup C, Mourgues S, Robert A, Meunier B. Heme alkylation by artesunic acid and trioxaquine D3/101, two antimalarial trioxanes. Journal of medicinal chemistry. 2005;48(4):653-8.

[26] Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985;228(4703):1049-55.

[27] Jung M, Lee K, Kim H, Park M. Recent advances in artemisinin and its derivatives as antimalarial and antitumor agents. Current medicinal chemistry. 2004; 11(10):1259-84.

[28] Christen P, Peuthely JL. New trends in extraction, identification and quantification of artemisinin and its derivatives. Current Medicinal Chemistry. 2001;8(15):1827-39.

[29] Chaturvedi D, Goswami A, Saikia PP, Barua NC, Rao PG. Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chemical Society Reviews. 2010;39(2):435-54.

[30] Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell. 2011; 146(6):855-8.

[31] Barnett DS, Guy RC. Antimalarials in development in 2014. Chemical reviews. 2014; 114(22):11221-41.

[32] Loo CS, Lam NS, Yu D, Su XZ, Lu F. Artemisinin and its derivatives in treating protozoan infections beyond malaria. Pharmacological research. 2017; 117:192-217.

[33] Barnett DS, Guy RC. Antimalarials in development in 2014. Chemical reviews. 2014;114(22):11221-41.

[34] Jansen FH, Soomro SA. Chemical instability determines the biological activity of the artemisinins. Current medicinal chemistry. 2007;14(30):3243-59.

[35] Vachot-Gané L, Khim N, Iannello A, Legrand E, Kim S, Eam R, Khean C, Kem M, Ashley E, Tun KM, Dhorda M. A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants. Malaria journal. 2018;17(1):375.

[36] Dutta GP. New Antimalarial Drug Discovery in India and Future Strategy for Malaria Control. Proceedings of the Indian National Science Academy. 2016;82(1).

[37] Olliaro PL, Taylor WR. Antimalarial compounds: from bench to bedside. Journal of experimental biological. 2003;206(21):3753-9.

[38] Qidwai T, K Yadav D, Khan F, Dhawan S, Bhabhakai R, GSIAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmodin II, a hemoglobin-degrading enzyme from P. falciparum. Current pharmaceutical design. 2012;18(37):6133-54.

[39] Posner GH. Antimalarial peroxides in the qinghaosu (artemisinin) and qinghaosu families. Expert Opinion on Therapeutic Patents. 1998;8(11):1487-93.

[40] Oh CH, Kim HJ, Wu SH, Won HS. A new type of 1, 2, 4-trioxanes structurally related antimalarial artemisinin. Tetrahedron letters. 1999; 40(48):8.391-4.

[41] Lapkin AA, Walker A, Sullivan N, Khambey B, Mambro B, Chemat S. Development of HPLC, analytical protocols for quantification of artemisinin in biomass and extracts. Journal of Pharmaceutical and Biomedical Analysis. 2009;49(4):908-15.

[42] Hao HD, Wittlin S, Wu Y. Potent Antimalarial 1, 2, 4-Trioxanes through Perhydrolysis of Epoxides. Chemistry-A European Journal. 2015;19(23):7605-19.

[43] Gupta AK, Chakraborty S, Srivastava K, Puri SK, Saxena AK. Pharmacophore modeling of substituted 1, 2, 4-Trioxanes for quantitative prediction of their antimalarial activity. Journal of chemical information and modeling. 2010;50(8):1510-20.